anaplastic large cell lymphoma


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

an·a·plas·tic large cell lym·pho·ma

a form of lymphoma characterized by anaplasia of cells, sinusoidal growth, and immunoreactivity with CD30 (Ki-1 or Ber-H2).
Synonym(s): Ki-1+ lymphoma

anaplastic large cell lymphoma

A primary non-B cell non-Hodgkin lymphoma, usually of T cell lineage, which is immunoreactive for CD30 and often ALK (anaplastic lymphoma kinase) and characterised by scattered to abundant “hallmark cells”—medium-sized cells with abundant cytoplasm and kidney-shaped nucleus, which tend to aggregate around blood vessels. ALCLs arise either as a primary neoplasm in a node or lymphoid tissue, soft tissue, lung, or skin, or secondary to the transformation of a lymphoproliferative disorder (e.g., mycosis fungoides), T-cell lymphoma, lymphomatoid papulosis or Hodgkin lymphoma.
DiffDx Classical Hodgkin lymphoma.
Clinical findings Often a late-presenting lymphoma with “B symptoms” including night sweating and weight loss.
Molecular >90% have rearrangement of T cell receptor, chromosomal translocation involving the nucleophosmin gene on chromosome 5.
Management CHOP, radiation for bulky disease.

anaplastic large cell lymphoma

Abbreviation: ALCL
A rare form of non-Hodgkin, T-cell lymphoma that may behave indolently when limited to the skin or may be more aggressive and spread to lymph nodes throughout the body.
See also: lymphoma
References in periodicals archive ?
Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics.
Primary anaplastic large cell lymphoma of the lung: a clinicopathologic study of five patients.
Primary endobronchial anaplastic large cell lymphoma in a pediatric patient.
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Cytologic and immunocytochemical findings of anaplastic large cell lymphoma.
Brentuximab vedotin has the potential to make a significant difference to patients with relapsed or refractory Hodgkin lymphoma or relapsed or refractory systemic anaplastic large cell lymphoma.
The analysis assessed the efficacy and safety of single-agent ADCETRIS among 22 systemic anaplastic large cell lymphoma (sALCL) patients, 16 HL patients and two patients with other CD30-positive malignancies.
19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers - Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).
Anaplastic large cell lymphoma usually shows T-cell receptor gene rearrangement in a monoclonal fashion detected by Southern blot analysis or PCR-based assay.
Long-term Remissions Observed in an Ongoing Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (Abstract #2745)
In the afternoon, the advisory committee discusses a biologics application for Adcetris for treatment of relapsed or standard treatment resistant systemic anaplastic large cell lymphoma.
The T lymphocytes of anaplastic large cell lymphoma will express lymphocytic antigens, specifically CD45 (common leukocyte antigen), CD30, and at least one pan-T-cell marker, which will be negative in most epithelioid angiosarcomas (Table).